Skip to main content
. 2020 Sep 1;117(9):2108–2124. doi: 10.1093/cvr/cvaa256

Figure 5.

Figure 5

Effects of treatment with Lira or Dapa on cardiac function, cardiac structure, and cardiac remodelling. (A) FS (systolic function) (n = 8–13 mice per group). (B) LVAWd (n = 12–14 mice per group). (C) GLS as marker of myocardial deformation (n = 9–13 mice per group). (D) LV/tibia, left ventricle weight corrected for tibia length (n = 13 mice per group). (E) Atria/tibia = atria weight corrected for tibia length (n = 13–15 mice per group). (F) Lung weight/tibia length (n = 13–14 mice per group). FS, fractional shortening; GLS, global longitudinal strain; LVAWd, left ventricle anterior wall thickness in diastole; dotted lines represents control reference values; HFD + ANGII + Dapa, high-fat diet + angiotensin II with dapagliflozin treatment; HFD + ANGII + Lira, high-fat diet + angiotensin II with daily liraglutide injection; HFD + ANGII + Saline, high-fat diet + angiotensin II with saline injections . Data are presented as mean + standard errors of the mean. *Kruskal–Wallis test followed by Mann–Whitney U test P <0.05 is considered significant.